Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346223 | 0.84 | NPC1 (0.55) | FASNKMT2AEPHX2MAPTPTK6 | |
| SCHEMBL1512353 | 0.78 | EPHX2 (0.43) | FASNEPHX2PTK6 | |
| SCHEMBL348757 | 0.78 | EPHX2 (0.58) | FASNEPHX2POLB | |
| SCHEMBL1829695 | 0.77 | SIGMAR1 (0.50) | KMT2APTK6POLBMEN1 | |
| SCHEMBL1512744 | 0.77 | FASN (0.42) | FASNKMT2AEPHX2PTK6MEN1 | |
| SCHEMBL1019694 | 0.75 | HTT (0.44) | KMT2ATP53MAPTMEN1 | |
| SCHEMBL13663414 | 0.75 | HTT (0.46) | KMT2AEPHX2TP53MAPTMEN1 | |
| SCHEMBL1512820 | 0.74 | RORC (0.49) | KMT2AEPHX2TP53MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL1019156 | 0.74 | KMT2A (0.47) | KMT2AEPHX2TP53MAPTMEN1 | |
| SCHEMBL12954855 | 0.72 | FAAH (0.50) | TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
| CN-102131781-A | 1-(4-ureidobenzoyl)piperazine derivatives | ORGANON NV | 2011-07-20 | — | — | CN | disclosed |
| EP-2318368-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. Organon (NL) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010025179-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | FASN 1591/4885KMT2A 4136/4885EPHX2 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.